Summary
Edwards Lifesciences (EW) filed an 8-K on February 1, 2017, primarily to report its fourth-quarter 2016 financial results. The filing itself is brief, mainly referencing a press release (Exhibit 99.1) which contains the detailed financial information. Investors should refer to this press release for specifics on revenue, earnings, and any forward-looking guidance provided by the company for the upcoming periods.
Key Highlights
- 1Edwards Lifesciences reported its Q4 2016 financial results via a press release furnished as part of this 8-K filing.
- 2The primary purpose of this 8-K is to disclose the company's financial performance for the fourth quarter of 2016.
- 3Investors need to consult Exhibit 99.1, the press release, for detailed financial metrics, including revenue and earnings per share for Q4 2016.
- 4The filing indicates that the information furnished under Item 2.02 is not considered 'filed' for the purposes of the Securities Exchange Act of 1934.
- 5No significant operational changes or material agreements were disclosed in the 8-K filing itself, beyond the financial results announcement.
Frequently Asked Questions
The main purpose of this 8-K filing is to publicly disclose Edwards Lifesciences' financial results for the fourth quarter of 2016, as detailed in an accompanying press release.
The specific financial results for the fourth quarter of 2016 are located in the press release furnished as Exhibit 99.1 to this 8-K filing.
While the 8-K itself does not contain guidance, the press release (Exhibit 99.1) that it references typically includes forward-looking statements and guidance from the company. Investors should review that document for any new outlook.
No, the information furnished under Item 2.02 of this 8-K, including the press release, is specifically noted as not being 'filed' for the purposes of the Securities Exchange Act of 1934. This means it is primarily for disclosure rather than triggering certain regulatory obligations.